# Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

> **NCT07247786** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fundación GECP** · enrollment: 68 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Respiratory Tract Neoplasm

## Interventions

- **BIOLOGICAL:** Biological: Fecal Microbiota Transplantation
- **DRUG:** Durvalumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin (AUC 6)

## Key facts

- **NCT ID:** NCT07247786
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2031-12-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247786, "Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07247786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*